Evaluation of Risk Factors for Premature Discontinuation of Injection Treatment With Betaferon in Patients With Relapsing Forms of Multiple Sclerosis.

Trial Profile

Evaluation of Risk Factors for Premature Discontinuation of Injection Treatment With Betaferon in Patients With Relapsing Forms of Multiple Sclerosis.

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Jun 2013

At a glance

  • Drugs Interferon beta-1b (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms BREAK
  • Sponsors Bayer
  • Most Recent Events

    • 27 Apr 2012 Actual initiation date changed from Nov 2008 to Sep 2008 as reported by ClinicalTrials.gov.
    • 27 Apr 2012 Actual patient number changed from 827 to 848 as reported by ClinicalTrials.gov.
    • 27 Apr 2012 Actual end date (Dec 2011 ) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top